Authors: Sharon Salt, Editor
ProMIS Neurosciences (Toronto, Canada) has announced that their oligomer-selective antibody therapeutic for Alzheimer’s disease (AD), PMN310, demonstrates potential for improved safety profile compared to other amyloid beta (Aβ)-directed antibodies in clinical development.
In a direct comparison to BAN2401 and aducanumab, the company revealed that PMN310 displayed no binding to Aβ plaque in AD brain samples. BAN2401 and aducanumab were both reported to have displayed robust Aβ reactivity.
Restricted Content / Members Only